Oryzon Genomics SA 2018 IR
The report is a registration document for Oryzon Genomics, S.A., approved on July 24, 2018. It provides comprehensive information about the company's business model, clinical pipeline, and financial performance for the years 2015 to 2017, as well as the first quarter of 2018. Key highlights include the clinical development of epigenetic drugs such as ORY-2001 for Alzheimer's disease and multiple sclerosis, and ORY-1001 for acute leukemia and small-cell lung cancer. The document also details the recovery of development and commercialization rights for ORY-1001 from Roche in January 2018.
Company: Oryzon Genomics SA
Sector: Manufacturing
Country: Spain
Year: 2018
Type: IR
Pages: 166
Back to company
Oryzon Genomics SA
Registration Document
The report is a registration document for Oryzon Genomics, S.A., approved on July 24, 2018. It provides comprehensive information about the company's business model, clinical pipeline, and financial performance for the years 2015 to 2017, as well as the first quarter of 2018. Key highlights include the clinical development of epigenetic drugs such as ORY-2001 for Alzheimer's disease and multiple sclerosis, and ORY-1001 for acute leukemia and small-cell lung cancer. The document also details the recovery of development and commercialization rights for ORY-1001 from Roche in January 2018.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
2017
Fiscal Year
2017
Published
Jul 24, 2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees